Edition:
United Kingdom

U.S. FDA Accepts For Priority Review Bristol-Myers Squibb's Application For Empliciti


Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Bristol-Myers Squibb Co ::U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS FOR PRIORITY REVIEW BRISTOL-MYERS SQUIBB’S APPLICATION FOR EMPLICITI (ELOTUZUMAB) PLUS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA.BRISTOL-MYERS SQUIBB CO - FDA GRANTED APPLICATION PRIORITY REVIEW WITH AN ACTION DATE OF DECEMBER 27, 2018.